JPH07509223A - インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 - Google Patents
インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法Info
- Publication number
- JPH07509223A JPH07509223A JP5519572A JP51957293A JPH07509223A JP H07509223 A JPH07509223 A JP H07509223A JP 5519572 A JP5519572 A JP 5519572A JP 51957293 A JP51957293 A JP 51957293A JP H07509223 A JPH07509223 A JP H07509223A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- tnf
- tnf inhibitor
- inhibitors
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
Claims (15)
- 1.治療効果のある量のIL−1インヒピターおよびTNFインヒピターを、そ の必要のある被験体に投与することを含む、TNF媒介疾患またはIL−1媒介 疾患である疾患を治療または予防する方法。
- 2.前記IL−1インヒピターがIL−1raである、請求項1に記載の方法。
- 3.請求項2に記載の方法であって、前記IL−1raが以下からなる群から少 なくとも1つの化合物を含む、方法:IL−1raα、IL−1raβ、および IL−1rax。
- 4.請求項1に記載の方法であって、前記TNFインヒピターが、以下からなる 群より選択される化合物を少なくとも1つ含む、方法:30kDaTNFインヒ ピター、40kDaTNFインヒピター、40kDaTNFインヒピターΔ51 、および40kDaTNFインヒピターΔ53。
- 5.前記IL−1raがヒト組換えIL−1raである、請求項2に記載の方法 。
- 6.前記TNFインヒピターがヒト組換え30kDaTNFインヒピターである 、請求項1に記載の方法。
- 7.請求項1に記載の方法であって、前記IL−1インヒピターがヒト組換えI L−1raであり、そして前記TNFインヒピターがヒト組換え30kDaTN Fインヒピターである、方法。
- 8.請求項1に記載の方法であって、前記IL−1インヒピターおよび前記TN Fインヒピターが薬学的に許容されるキャリア中で投与される、方法。
- 9.請求項1に記載の方法であって、前記疾患が以下からなる群より選択される 、方法:関節炎、炎症性腸疾患、敗血症性ショック、虚血性障害、再灌流障害、 骨粗鬆症、喘恩、インスリン性糖尿病、骨髄性白血病、他の白血病、乾癬、成人 呼吸促進症候群、悪液質/食欲不振、および肺繊維症。
- 10.薬学的に許容されるキャリア中にIL−1インヒピターおよびTNFイン ヒピターを含む薬物組成物。
- 11.前記IL−1インヒピターがIL−1raである、請求項10に記載の薬 物組成物。
- 12.請求項11に記載の薬物組成物であって、前記1L−1raが以下からな る群から少なくとも1つの化合物を含む、薬物組成物:IL−1raα、 IL −1aβ、およびIL−1rax。
- 13.請求項10に記載の薬物組成物であって、前記TNFインヒピターが以下 からなる群より選択される少なくとも1つの化合物を含む、薬物組成物:30k DaTNFインヒピター、40kDaTNFインヒピター、40kDaTNFイ ンヒピターΔ51、および40kDaTNFインヒピターΔ53。
- 14.請求項13に記載の薬物組成物であって、前記TNFインヒピターがヒト 組換え30kDaTNFインヒピターである、薬物組成物。
- 15.請求項14に記載の薬物組成物であって、前記IL−1インヒピターがヒ ト組換えIL1−1raである、薬物組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87634492A | 1992-04-30 | 1992-04-30 | |
US876,344 | 1992-04-30 | ||
PCT/US1993/004141 WO1993021946A1 (en) | 1992-04-30 | 1993-04-28 | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001365407A Division JP2002220342A (ja) | 1992-04-30 | 2001-11-29 | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH07509223A true JPH07509223A (ja) | 1995-10-12 |
Family
ID=25367492
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5519572A Pending JPH07509223A (ja) | 1992-04-30 | 1993-04-28 | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
JP2001365407A Pending JP2002220342A (ja) | 1992-04-30 | 2001-11-29 | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001365407A Pending JP2002220342A (ja) | 1992-04-30 | 2001-11-29 | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0639079B1 (ja) |
JP (2) | JPH07509223A (ja) |
AT (1) | ATE188610T1 (ja) |
AU (1) | AU672606B2 (ja) |
CA (1) | CA2118119C (ja) |
DE (1) | DE69327582T2 (ja) |
DK (1) | DK0639079T3 (ja) |
ES (1) | ES2142341T3 (ja) |
GR (1) | GR3033144T3 (ja) |
PT (1) | PT639079E (ja) |
WO (1) | WO1993021946A1 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
CA2139385C (en) * | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US7005413B1 (en) | 1995-12-22 | 2006-02-28 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
CA2273852C (en) | 1996-12-06 | 2009-09-29 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
EP2003203A1 (en) | 1996-12-23 | 2008-12-17 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
DE122010000049I1 (de) | 1997-04-15 | 2011-05-05 | Daiichi Sankyo Co Ltd | Neues protein und verfahren zu dessen herstellung |
ID23855A (id) | 1997-04-16 | 2000-05-25 | Amgen Inc | Protein pengikat osteoprotegerin dan reseptor |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
US6013253A (en) * | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
WO2000029581A1 (en) | 1998-11-13 | 2000-05-25 | Immunex Corporation | Human tslp dna and polypeptides |
IL145714A0 (en) * | 1999-04-02 | 2002-07-25 | Interleukin Genetics Inc | Prediction of risk of interstitial lung disease |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
AU6078500A (en) * | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
EP1282435A2 (en) * | 2000-05-12 | 2003-02-12 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
ES2674888T3 (es) | 2001-06-26 | 2018-07-04 | Amgen Inc. | Anticuerpos para OPGL |
AU2002359238B2 (en) | 2001-07-23 | 2008-01-17 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
CA2481074A1 (en) | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
EP2213685B1 (en) | 2002-09-06 | 2013-11-27 | Amgen Inc. | Therapeutic anti-IL-1R1 monoclonal antibody |
EP1793856A2 (en) * | 2004-08-20 | 2007-06-13 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
US7795385B2 (en) * | 2004-12-17 | 2010-09-14 | Bexar Global, Inc. | Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder |
PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
US9383348B2 (en) | 2008-06-21 | 2016-07-05 | John E. Repine | Compositions and methods for treating lung disorders |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
JP5746191B2 (ja) * | 2009-10-19 | 2015-07-08 | ハナル バイオファーマ カンパニーリミテッドHanAll Biopharma Co., Ltd. | 修飾されたヒト腫瘍壊死因子受容体−1ポリペプチドまたはその断片及びその製造方法 |
LT2523688T (lt) | 2010-01-15 | 2018-03-12 | Kirin-Amgen, Inc. | Antikūno kompozicija ir terapiniai režimai |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
KR102530900B1 (ko) | 2014-03-31 | 2023-05-12 | 암젠 케이-에이, 인크. | 손발톱 및 두피 건선의 치료 방법 |
WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
WO2018022982A1 (en) | 2016-07-29 | 2018-02-01 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
US20210236599A1 (en) | 2018-08-13 | 2021-08-05 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0148009B1 (ko) * | 1988-05-27 | 1998-08-01 | 그래고리 비. 아보트 | 인터루킨-1 억제제 |
IL95031A (en) * | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
JPH0357034U (ja) * | 1989-10-11 | 1991-05-31 | ||
KR100234520B1 (ko) * | 1991-01-18 | 1999-12-15 | 그레고리 아보트 | 종양괴사인자 매개병 치료용 의약품 조성물 |
-
1993
- 1993-04-28 PT PT93910992T patent/PT639079E/pt unknown
- 1993-04-28 CA CA002118119A patent/CA2118119C/en not_active Expired - Lifetime
- 1993-04-28 AU AU42294/93A patent/AU672606B2/en not_active Expired
- 1993-04-28 WO PCT/US1993/004141 patent/WO1993021946A1/en active IP Right Grant
- 1993-04-28 EP EP93910992A patent/EP0639079B1/en not_active Expired - Lifetime
- 1993-04-28 AT AT93910992T patent/ATE188610T1/de active
- 1993-04-28 DK DK93910992T patent/DK0639079T3/da active
- 1993-04-28 JP JP5519572A patent/JPH07509223A/ja active Pending
- 1993-04-28 ES ES93910992T patent/ES2142341T3/es not_active Expired - Lifetime
- 1993-04-28 DE DE69327582T patent/DE69327582T2/de not_active Expired - Lifetime
-
2000
- 2000-04-04 GR GR20000400837T patent/GR3033144T3/el unknown
-
2001
- 2001-11-29 JP JP2001365407A patent/JP2002220342A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2142341T3 (es) | 2000-04-16 |
DE69327582T2 (de) | 2000-08-03 |
CA2118119A1 (en) | 1993-11-11 |
AU4229493A (en) | 1993-11-29 |
AU672606B2 (en) | 1996-10-10 |
PT639079E (pt) | 2000-04-28 |
WO1993021946A1 (en) | 1993-11-11 |
JP2002220342A (ja) | 2002-08-09 |
DE69327582D1 (de) | 2000-02-17 |
DK0639079T3 (da) | 2000-06-13 |
EP0639079B1 (en) | 2000-01-12 |
EP0639079A1 (en) | 1995-02-22 |
ATE188610T1 (de) | 2000-01-15 |
CA2118119C (en) | 2001-07-31 |
GR3033144T3 (en) | 2000-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07509223A (ja) | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 | |
RU2166955C2 (ru) | Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток | |
DE69724451T2 (de) | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen | |
ES2377935T3 (es) | Procedimiento para dirigir células que expresan receptor -3 o -2 del factor de crecimiento de fibroblastos | |
EP1330260B1 (en) | Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia | |
JPH02262593A (ja) | 血管発生病の処置に有用な薬剤及び新規な蛋白質 | |
KR19990082399A (ko) | 인터루킨-1 저해제 및 조절 방출 중합체를 함유하는 조성물 | |
KR20000023695A (ko) | 절두된 가용성 종양 괴사 인자 ⅰ형 및 ⅱ형 수용체 | |
PT726778E (pt) | Sistema de administracao oral de proteinas g-csf modificadas quimicamente | |
US20080292628A1 (en) | Chimeric Protein | |
JPH06503320A (ja) | 再活性化酸素種に対する防御剤の使用 | |
JP3030386B2 (ja) | 抗ガン剤 | |
EP1058544B1 (en) | Inhibition of tnf activity with compositions comprising heparin and soluble tnf recpetors | |
WO2006110577A2 (en) | Use of fril proteins for reducing the production of pro-inflammatory cytokines | |
AU2005326226B2 (en) | Immunopotentiating agent | |
CA2456247C (en) | Use of il-18 inhibitors in hypersensitivity disorders | |
Atarashi et al. | A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: Implication for immunotherapy of human hepatocellular carcinoma | |
AU2002331376A1 (en) | Use of IL-18 inhibitors in hypersensitivity disorders | |
JP2010509364A (ja) | 創傷治癒における使用のためのil−17b | |
AU784768B2 (en) | Methods for treating cytokine mediated diseases | |
JPH083065A (ja) | 肝臓障害に対する治療剤 | |
JP3246670B2 (ja) | インターロイキン−2と5’−デオキシ−5−フルオロウリジンとを含有してなる抗癌剤 | |
JP3640254B2 (ja) | 間質性肺炎治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040525 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040823 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051206 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060306 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061122 |